|
03 Aug 2021 |
Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor
|
|
03 Aug 2021 |
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
|
|
02 Aug 2021 |
Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer
|
|
02 Aug 2021 |
Cytokinetics Announces Start of COURAGE-ALS, a Phase 3 Clinical Trial of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis
|
|
02 Aug 2021 |
Biophytis Announces Top Line Results of SARA-INT Phase 2 Study With Sarconeos (BIO101) in Sarcopenia
|
|
02 Aug 2021 |
Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia
|
|
31 Jul 2021 |
Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies
|
|
30 Jul 2021 |
Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration
|
|
30 Jul 2021 |
Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
|
30 Jul 2021 |
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
|
|
28 Jul 2021 |
Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
|
|
28 Jul 2021 |
Disc Medicine Initiates Phase 1 Clinical Study of DISC-0974, a First-In-Class Inhibitor of Hemojuvelin (HJV) in Development for the Treatment of Anemia of Inflammation
|
|
28 Jul 2021 |
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
|
|
28 Jul 2021 |
Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers
|
|
28 Jul 2021 |
ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
|
|
28 Jul 2021 |
Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
|
|
28 Jul 2021 |
NewAmsterdam Pharma Reports Positive Results from Phase 2 Study of Oral Obicetrapib Demonstrating Over 50% LDL-Lowering as an Adjunct to High-Intensity Statins
|
|
28 Jul 2021 |
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
|
|
28 Jul 2021 |
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
|
|
28 Jul 2021 |
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
|
|
28 Jul 2021 |
BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations
|
|
28 Jul 2021 |
Grünenthal's Glucocorticoid Receptor Modulator enters clinical development
|
|
28 Jul 2021 |
Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
|
|
28 Jul 2021 |
Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
|
|
28 Jul 2021 |
Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)
|
